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A B S T R A C T 
Colorectal cancer is one of the top three cancers 
in the world in terms of incidence. Colonoscopy, 
which many regard as the gold standard in 
diagnosis of colonic polyps and neoplasm, is 
costly, invasive and labour-intensive, and deemed 
an unsuitable population-wide index screening 
tool. Alternative modalities, including guaiac and 
immunohistochemical faecal occult blood tests, 
computed tomographic colonography, colon capsule 
endoscopy, flexible sigmoidoscopy, and double-
contrast barium enema are available. The procedures, 
test characteristics, and their implications are 
reviewed. Immunohistochemical faecal occult blood 
testing appears to be the most suitable population-
wide screening test for an average-risk population, 
with flexible sigmoidoscopy as an alternative. 
More evidence is needed to determine the role of 
Alternatives to colonoscopy for population-wide 
colorectal cancer screening
Introduction
Colorectal cancer (CRC) became the second and 
third most common cancer in women and men in 
2012.1 Most cases of CRC arise from adenoma, 
the process known as the adenoma-carcinoma 
sequence, and are therefore amenable to screening 
and early treatment.2-4 Ecological studies have shown 
that 2.6% to 5.6% of advanced adenoma progress to 
CRC annually.5
 Colonoscopy remains the gold standard for 
diagnosis,6 and has even been used as a primary 
screening method in some countries (eg the US). 
Nonetheless its use in most countries as an index 
tool for mass screening of an average-risk population 
is impractical due to its cost, invasiveness, and need 
for expertise (ie endoscopists).
 In this study, we reviewed the literature about 
the procedures, test characteristics, and implications 
of the following alternative screening modalities: 
guaiac faecal occult blood testing (gFOBT), 
immunohistochemical faecal occult blood testing 
(iFOBT), computed tomographic colonoscopy 
(CTC), colon capsule endoscopy (CCE), flexible 
sigmoidoscopy (FS), and double-contrast barium 
enema (DCBE).
Guaiac faecal occult blood testing
The gFOBT offers the strongest evidence as a suitable 
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screening tool for CRC. Its mechanism involves 
detection of haemoglobin in the stool. The test is not 
specific for human haemoglobin however, and false-
positive results can arise due to plant peroxidases 
and heme in red meat. False negatives can occur 
when stool contains certain chemicals, eg vitamin 
C. It also detects bleeding from the gastro-intestinal 
(GI) tract other than the colon and rectum. Two or 
more samples are usually required.
 Four large-scale randomised controlled trials 
(RCTs) of gFOBT with long-term follow-up have been 
conducted; they include Minnesota study in the 
US,7 Nottingham trial in the UK,8 Göteborg study in 
Sweden,9 and Funen study in Denmark.10 A total of 
328 767 individuals, aged 45 to 80 years, were involved. 
The results consistently showed reduction in CRC 
mortality by 12% to 33%, after up to 30 years of 
follow-up.7-10 The results are summarised in Table 1.
 In screening for significant or advanced 
adenoma, test sensitivity was 23.8%,11 and specificity 
was 97.7% to 99.0% with positive predictive values 
(PPVs) of 39.0% to 55.3%. The detection rate in 
intention-to-screen (ITS) analysis was 0.6% and 
that in per protocol (PP) analysis was 1.2%. The 
NNScreen, or the number of average-risk individuals 
needed to recruit in a screening programme to 
detect one advanced adenoma, was 84 to 181.12,13 
The NNScope, or the number of colonoscopies 
needed to diagnose an advanced adenoma after 
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全民大腸癌篩查：大腸鏡檢查的替代方案
梁俊彥、傅志聰、陳子泰、蔣文豐、林凱健、陳羲和、張清林
大腸癌是全球發病率最高的三大癌症之一。大腸鏡檢查被認為是診斷
大腸息肉和腫瘤的金標準，可惜這種方法成本高，屬侵入性檢查和勞
動密集型，所以被認為不適合作全民篩查的工具。其他替代大腸鏡檢
查的方案包括愈創木脂和免疫化學大便隱血測試、電腦斷層結腸成
像、結腸膠囊內視鏡檢查、乙狀結腸內視鏡檢查和雙對比鋇劑灌腸。
本文綜述了這些替代方案的程序、試驗特點及可能的影響。要開展無
症狀全民大腸癌篩查，似乎免疫化學大便隱血測試最為適合，其次為
乙狀結腸內視鏡檢查。至於電腦斷層結腸成像和結腸膠囊內鏡檢查方
面，則須搜集更多有關其作為篩檢工具的證據。
screening revealed a likely significant lesion, was 
2.2.12 Although NNScreen is useful in assessing each 
modality individually, NNScope of a test provides 
additional information about the role of gFOBT in 
a screening programme to select patients for further 
diagnostic colonoscopy. For CRC, the sensitivity was 
54.2%, and specificity ranged from 96.9% to 98.1% 
with a PPV of 5.2% to 13.6%. Detection rate in ITS 
analysis was 0.1%, while that in PP analysis was 0.2%. 
The NNScreen was 392 to 936 and the NNScope was 
10.3.11-14
 The Funen study10 showed the CRC mortality 
dropped from 18% to 11% after five screening 
rounds, as a result of decreased compliance. Similar 
findings were echoed in the Tenerife study in Spain.11
Immunochemical faecal occult 
blood testing
The iFOBT employs an antibody-based assay, detect-
ing globin or early degradation products of human 
haemoglobin.15 The antibodies used are human-
specific, thus the number of false positives due to 
non-human blood is minimised. As globin is more 
rapidly degraded than heme throughout the GI tract, 
less upper GI tract bleeding is detected. It requires 
no dietary restrictions16 and has a participation rate 
of 38.9% to 71.9%.17-19 The results can be qualitative 
or quantitative.20 Sampling technique, distribution 
of blood in faeces, and sample instability make true 
quantification difficult, however.15 Adjustment of 
performance parameters is possible by altering the 
cut-off values. It is generally agreed that a cut-off 
of 75 ng/mL provides a balance between higher 
detection rate and lower NNScope.12,15,18,21,22 It should 
also be noted though that different brands of iFOBT 
kits may yield different results even when the same 
cut-off is used.
 The iFOBT on one or two consecutive faecal 
samples is recommended. A study showed that 1-day 
sampling had a higher miss rate for CRC compared 
with 2-day sampling.23 Another study showed that 
performing iFOBT at 1-, 2-, or 3-year intervals 
did not yield significantly different results in terms 
of advanced adenoma detection, but compliance 
decreased with frequent screening.24
 The stability of the iFOBT kit is temperature-
dependent, making results vulnerable to changes in 
environmental temperature and the sample return 
time.20 In moderate climates, the sample return 
time should not exceed 7 days.25 Manufacturers 
are developing buffer solutions to overcome this 
problem.15 
 A potential disadvantage of iFOBT is its 
decreased sensitivity to proximal colonic lesions. 
A German study showed a sensitivity of 33% and 
20% for left- and right-sided lesions, respectively. 
Nonetheless the results were statistically 
insignificant,26 and were contradictory to another 
Dutch trial.27 
 The positivity rate of iFOBT ranges from 5.5% 
to 11.0%.12,13,17,19,28,29 The sensitivity and specificity for 
CRC ranges from 53.3% to 94.1% and 87.5% to 96.9%, 
respectively.18,28,30,31 The PPV ranges from 5.2% to 
12.8% at a cut-off value of 75 ng/mL.12,13,17-19,28-32 The 
NNScreen and NNScope ranges from 213 to 936 and 
TABLE 1.  Summary of four randomised controlled trials comparing screening with guaiac faecal occult blood testing with no screening* 7-10
Study Year Screening Control Follow-up 
duration 
(years)
Age at 
recruitment 
(years)
Reduction in 
CRC mortality 
(%)
Relative reduction in 
CRC mortality (95% CI)
Shaukat et al7 2013 15 570 (annual);
15 587 (biennial)
15 394 30 50-80 33
20
0.68 (0.56-0.82)
0.78 (0.65-0.93)
Scholefield et al8 2012 76 056 75 919 0.0-28.4 45-74 12† 0.88 (0.79-0.98)†
Lindholm et al9 2008 34 144 34 164 11.3-19.5 60-64 16 0.84 (0.71-0.99)‡
Kronborg et al10 2004 30 967 30 966 17 45-75 17 0.84 (0.73-0.96)
Abbreviations: CI = confidence interval; CRC = colorectal cancer
* Intention-to-treat analysis 
† Calculation based on the first 12 years of study
‡ Odds ratio used in original article, relative risk calculated for representation here
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9.8 to 17.3, respectively.12,13,17,19,28-30,32 These results 
are summarised in Table 2. For advanced adenoma, 
the sensitivity and specificity ranges from 33.9% to 
41.3% and 91.4% to 97.3%, respectively.18,28,31 The 
PPV ranges from 49.0% to 51.8%.12,13 The NNScope 
and NNScreen ranges from 2.2 to 2.4 and 88.0 to 
135.6, respectively (single sample).29
 Compared with gFOBT, studies in the literature 
showed superior results for iFOBT that generally had 
a higher positivity rate, often 2 times higher than that 
of gFOBT.13,28 The detection rate for CRC in a study 
by Faivre et al32 was 1.6 to 2.1 times higher than in 
gFOBT. This was echoed by another large-scale RCT 
which showed a significantly higher detection rate 
using iFOBT.13 Studies showed the detection rate 
for advanced adenoma using iFOBT to be at least 
double that of gFOBT.12,29 In the study by Faivre et 
al,32 iFOBT was 1.7 to 2.1 times more sensitive than 
gFOBT for CRC.32 A study by Brenner and Tao30 
showed significantly higher PPV for iFOBTs than 
gFOBTs (7.3%-10.0% vs 4.5%). In two comparative 
studies, the NNScreen of iFOBT was about half 
that of gFOBT29,32; iFOBT also had a 13.0% to 15.0% 
higher participation rate than gFOBT.13,15,16,20,33
 The iFOBT is more costly than its guaiac-
based counterpart,20 but modelling studies showed 
that it is more cost-effective.34-37 This is largely 
explained by the higher participation rate, detection 
rate, sensitivity and PPV, and with lower NNScope 
and NNScreen. There is a general consensus that it 
should replace gFOBT.16,20,38
Computed tomographic 
colonography
The CTC was first described in 1994.39 It provides 
a non-invasive structural assessment of the colon. 
Compared with conventional colonoscopy, CTC is 
sedation-free and has an extremely low risk of bowel 
perforation (0.005%-0.059%).40,41 Furthermore, 
TABLE 2.  Studies showing performance of iFOBT, with or without comparison with gFOBT12,13,17-19,28-32
Study Country Year Screening 
tests*
Total No. Age 
(years)
Sensitivity (%) 
(95% CI)
PPV for CRC 
(%) [95%CI]
NNScope 
(95%CI)
NNScreen 
(95%CI)
Allison et al28† United States 2007 gFOBT2
iFOBT7
N/A ≥50 64.3 (35.6-86.0)
81.8 (47.8-96.8)
1.5 (0.8-3.0)   
5.2 (2.6-10.0)
N/A 528.1
672.2
Levi et al18 Israel 2007 iFOBT2 1859 N/A 88.2 (72.9-100)‡
94.1 (82.9-100)§
12.9‡
11.9§
N/A N/A
van Rossum 
et al13
The Netherlands 2008 gFOBT1
iFOBT2
10 322
10 301
50-75 N/A 10.7 (4.7-16.6)  
8.6 (5.3-11.9)
9.4
11.7
430.1
936.5
Hol et al12 The Netherlands 2009 gFOBT1
iFOBT2
4843
4796
50-74 N/A 10.0 (4.0-20.0)  
10.0 (6.0-17.0)
10.3
9.8
392.0
213.0
Fu et al19 Singapore 2009 iFOBT2 751 40-85 78.8 5.3 17.3 250.3
Park et al31 Korea 2010 gFOBT1
iFOBT2
N/A 50-75 30.8 (9.1-61.4)
92.3 (64.0-99.8)
6.7 (1.8-15.9)  
12.8 (6.6-21.7)
N/A N/A
Faivre et al32 France 2012 gFOBT1
iFOBT2
iFOBT5
iFOBT6
85 149
32 215
19 244
33 690
50-74
2.1 (1.6-2.8)∥
1.7 (1.3-2.1)
1.8 (1.3-2.3)
5.2-6.4
5.6 (4.3-6.9)   
3.9 (2.9-4.9)   
5.7 (3.9-7.1)
12.8 (10.8-15.9)
16.6 (13.9-20.7)
12.7 (10.3-16.6)
366 (303-455)   
354 (286-435)   
296 (238-385)
Tan et al17 Singapore 2013 iFOBT1 20 989 ≥50 N/A 6.7 15.0 636.0
Brenner and 
Tao30
Germany 2013 gFOBT1
iFOBT2
iFOBT3
iFOBT4
N/A 50-79 33.3
73.3
60.0
53.3
4.5
10.0
8.1
7.3
N/A N/A
Raginel et al29 France 2013 gFOBT1
iFOBT2
iFOBT6
N/A 50-74 N/A 6.9
6.2
6.5
14.6
16.2
15.1
1041.9
549.9
449.9
Abbreviations: CI = confidence interval; CRC = colorectal cancer; gFOBT = guaiac faecal occult blood testing; iFOBT = immunohistochemical faecal occult 
blood testing; N/A = not available; NNScope = the number of colonoscopies needed to diagnose an advanced adenoma after screening revealed a likely 
significant lesion; NNScreen = the number of average-risk individuals needed to recruit in a screening programme to detect one advanced adenoma; PPV = 
positive predictive value
* gFOBT1 = Hemoccult II; gFOBT2 = Hemoccult Sensa; iFOBT1 = OC-Light; iFOBT2 = OC-SENSOR; iFOBT3 = RIDASCREEN Haemoglobin;  
iFOBT4 = RIDASCREEN Haemo-/Haptoglobin Complex; iFOBT5 = FOB-Gold; iFOBT6 = Magstream; iFOBT7 = FlexSure OBT
† Studied distal colorectal cancer only
‡ Cut-off value at 100 ng/mL
§ Cut-off value at 75 ng/mL
∥ Sensitivity ratio (ratio of true positives with iFOBT to that with gFOBT) was estimated as sensitivities could not be directly calculated
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assessment of the extra-colonic organs can be 
performed at the same time.42 A lower volume bowel 
preparation may be used43 and the radiation risk is 
negligible.41 Its main disadvantage is that biopsy is 
not possible, and the patient may require a second 
procedure with another bowel preparation, thus 
imposing additional costs and discomfort to the 
patient. Its role in CRC screening remains debatable. 
The American Cancer Society supports screening 
with CTC every 5 years.44 Other guidelines including 
the National Institutes of Health Asia Pacific 
Consensus Recommendations do not support its use, 
however, stating its lack of evidence as a screening 
technique in an average-risk population.45,46
 Studies of CTC in the literature use detection of 
polyps in general as the end-point. Data for detection 
of invasive carcinoma as well as reduction in CRC 
mortality were not available. Different studies use 
either ‘per patient’ or ‘per polyp’ for analysis. Two 
large US trials supported CTC as a screening tool 
in asymptomatic average-risk populations.47,48 Per-
patient analyses demonstrated a sensitivity of 78.0% 
to 93.8%, and specificity of 79.6% to 96.0%, respect-
ively.47,48 Meta-analyses in 2011 and 2014 reviewed 
15 trials,49,50 including the two aforementioned 
studies. All trials focused on a population aged 
over 50 years with average risk. Martín-López et 
al49 showed an overall per-patient sensitivity and 
specificity for CTC of 66.8% and 80.3%, which was 
lower than that of colonoscopy of 92.5% and 73.2%, 
respectively. The sensitivity and specificity were 
higher for larger polyps. For polyps larger than 1 
cm, the sensitivity was 91.2% and specificity 87.3%. 
Another meta-analysis reported sensitivities for 
≥6-mm and ≥10-mm polyps as 75.9% and 83.3% and 
specificities as 94.6% and 98.7%, respectively.50 
 Estimation of the cost-effectiveness remains 
complicated. Based on a systematic review of 16 
studies,51 the cost-effectiveness of CTC remains 
controversial. There is generally a stronger prefer-
ence for CTC over colonoscopy in asymptomatic 
individuals,52 although some may hold an opposite 
opinion due to more pain and discomfort in CTC.53 
The use of ‘low-prep’ or laxative-free CTC is being 
further investigated.43
 The CTC can detect asymptomatic polyps and 
has the potential to prevent them from progressing 
to advanced adenoma and CRC. These polyps may 
not be detected by gFOBT or iFOBT until they result 
in microscopic haemorrhage in the lower GI tract. 
This is an advantage of CTC compared with gFOBT 
and iFOBT. The role of CTC in reducing CRC 
mortality remains uncertain, however.
Colon capsule endoscopy
The CCE makes use of a double-headed capsule with 
a wide viewing angle, visualising the colon beyond 
the haustral folds.54 Its sensitivity and specificity 
for significant polyps has been reported to be 83% 
and 89%, respectively.55-57 The European Society of 
Gastrointestinal Endoscopy recommends CCE as 
an alternative screening method for average-risk 
individuals.58 In February 2014, it also received the US 
Food and Drug Administration clearance for use in 
patients following incomplete colonoscopy. It is also 
proven to be beneficial when the patient is unwilling 
or is unable to undergo colonoscopy.59,60 With its 
presumed increased uptake, it is a promising new 
CRC screening modality.61 The newest generation of 
CCE has improved resolution by adapting its frame 
rate to the speed of capsule movement. Some newer 
capsules also have four cameras to provide a 360-
degree view.62
 Despite its promising role in screening, some 
disadvantages of CCE have limited its use thus far. 
Strict bowel preparation, diet restrictions, and use 
of suppositories and prokinetics may be needed 
to ensure a smooth and quick journey of the 
capsule through the bowel, while minimising the 
interference of debris when identifying lesions.63 
Potential complications include capsule impaction 
and retention (1.4%64) that may require endoscopic 
or surgical removal. It is also not recommended in 
pregnancy or with implanted electromedical devices 
such as pacemakers.62 The cost of CCE is much 
higher than that of colonoscopy,65 and includes the 
reading of the captured video footage. There is also 
no current evidence to prove the mortality benefit of 
CCE use in CRC.
Flexible sigmoidoscopy
The FS examines the distal 40 to 60 cm of the lower GI 
tract. Full colonoscopy can be performed when there 
are positive findings. Compared with colonoscopy, 
it requires a simpler bowel preparation and dietary 
restriction is not necessary.66
 In two large-scale RCTs that involved 170 432 
and 55 736 individuals, in PP analysis, there was a 
43.0% reduction in CRC mortality and improved 
hazard ratio of 0.41.67,68 This was echoed by another 
RCT that involved 77 445 patients and showed a 21% 
reduction in the incidence of both proximal and distal 
cancer and a 50% reduction in mortality from distal 
cancer.69 The PPV was 91.9% for any adenoma.70 The 
positivity rate for adenoma was 17.3%.71 Most studies 
were in individuals aged ≥5070-72 or ≥55 years.68,69,73
 The sensitivity of FS depends on the adequacy 
of mucosal inspection and is operator-dependent.73 
Studies have shown inadequate screening in up 
to 91.7% of cases, ie <50 cm depth of insertion.73 
The technique had relatively low and fluctuating 
participation rates (20.9%-63.0%).70,71 A 35.3% 
decrease in adherence from baseline to subsequent 
study was observed.69
 The impact of FS as a screening tool is well 
established in the literature and accepted in various 
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screening protocols.44,46 This technique should be 
included as an alternative choice for a population-
wide screening programme, and the shortage of 
endoscopists could be partially addressed by training 
specialised nurses in the procedure.74
Combining flexible sigmoidoscopy with 
guaiac and immunohistochemical faecal 
occult blood testing
Flexible sigmoidoscopy cannot replace the role of 
colonoscopy in individuals with a positive faecal 
occult blood test.72 In a non-randomised trial, the 
detection rate of combined gFOBT and FS for 
cancer was higher than that of gFOBT alone (1.5 vs 
0.7 per 1000), but was not superior to FS alone (1.5 
vs 5.2 per 1000).70 Results were similar for advanced 
neoplasia. 
Double-contrast barium enema
The DCBE involves an X-ray study of the colon 
and rectum following injection of air and barium 
transrectally. Once regarded as a routine screening 
tool, its role has diminished since the introduction 
of other screening modalities. While it was the safest 
screening method next to FOBT with a perforation 
rate of 1 in 25 000,75 the sensitivity for polyps of 
≥10 mm was only 48%, rendering it suboptimal for 
screening.76,77 
Combining double-contrast barium enema 
with flexible sigmoidoscopy
When DCBE was combined with FS, they had 
the same sensitivity for cancer as colonoscopy 
(96.7%).78 Two RCTs in the 1990s reported a lower 
detection rate for small polyps for FS plus DCBE 
when compared with colonoscopy.79,80 Nonetheless 
the detection rate for cancers and large polyps was 
comparable.79 Sensitivity analyses in both studies 
revealed that in screening, FS plus DCBE was less 
cost-effective than colonoscopy.
Current guidelines 
The Asia Pacific Consensus Recommendations in 
2015 suggested the use of iFOBT over gFOBT, and 
FS and colonoscopy were deemed effective.46 On the 
contrary, CTC and CCE were not recommended 
for screening. In the US, surveillance programme 
guidelines from the American Cancer Society 
provided two sets of test options for asymptomatic 
adults aged ≥50 years.44 For adenomatous polyps 
and cancer, FS, DCBE, or CTC every 5 years, or 
colonoscopy every 10 years was recommended. 
For cancer alone, annual gFOBT or iFOBT testing 
was recommended. The American College of 
Gastroenterology supported replacement of 
gFOBT by iFOBT as a first-line screening test.81 The 
National Health Service in the UK recommends 
screening for average-risk men and women aged 60 
to 74 years with FOBT every 2 years.82 The European 
Union did not offer a comprehensive system, with 
a recommendation of FOBT for men and women 
aged 50 to 74 years.83 The Australian government 
encouraged biennial iFOBT for an asymptomatic 
population aged >50 years.84
 There is no formal consensus on a CRC 
screening programme in Hong Kong. The Hong 
Kong Cancer Fund, a cancer support organisation, 
recommends screening of the average-risk 
population aged ≥50 years, with either FOBT every 
year, FS or DCBE every 5 years, or colonoscopy every 
10 years.85
Discussion
Colonoscopy remains the gold standard 
diagnostic tool for CRC, but its costs, discomfort, 
inconvenience, and potential complications render 
it impractical as the first-line investigation in a 
population-wide CRC screening programme for 
average-risk individuals. Multiple alternative tools 
have since been developed, aimed at minimising 
discomfort and inconvenience and thus achieving 
better compliance, while at the same time not 
jeopardising the screening effectiveness. While it is 
not possible for these tools to replace colonoscopy 
for diagnosis, they may assume an essential role in a 
screening programme as an index investigation for 
risk stratification, thus selecting patients to undergo 
further diagnostic colonoscopy.
 These screening modalities differ in their 
development. Both gFOBT and FS are time-
honoured, heavily researched, and proven to reduce 
CRC mortality. Large amounts of research data are 
emerging in support of newer options such as iFOBT 
and CTC. While comparison of gFOBT and iFOBT 
is easily achievable, direct comparison of CTC 
and iFOBT is more difficult as there are different 
‘performance’ parameters. 
 The technique iFOBT is evolved from gFOBT 
and shares a similar mechanism. While gFOBT has 
been well proven by long-duration RCTs to reduce 
CRC mortality, it has been postulated that iFOBT 
may achieve the same effect. For a population-wide 
screening programme to be successful, the test 
has to be acceptable to asymptomatic individuals. 
This eventually determines the penetration and 
compliance with the programme. Compared with 
gFOBT, iFOBT undeniably has a higher participation 
rate,13,20,33 and even more so compared with FS.70,71 In a 
population-wide screening programme with iFOBT, 
implementation could be achieved in a relatively 
short period of time as it could be performed by 
primary care physicians and nurses. Installation 
of sophisticated hardware is not required. Given a 
positivity rate of 5.5% to 11.0%,12,13,17,19,28,29 however, 
it would have a significant impact on health care 
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services. A major increase in the number of referrals 
for colonoscopy would be anticipated and thus 
require a corresponding increase in the availability 
of endoscopy centres and endoscopists.
 Test characteristics are not the only factor 
that dictates the success of a screening programme; 
compliance plays a crucial role. Studies have shown 
that those who communicate well with their health 
care providers are more likely to adhere to a screening 
programme.86 When implementing a population-
wide programme, recruiting primary care physicians 
to promote CRC screening and perform office-based 
iFOBT would be logical and is feasible. 
Conclusion
Each CRC screening modality has its own niche, 
providing unique prognostic benefits but with their 
own shortcomings. Based on the available evidence 
to date, feasibility, and participant acceptance, 
iFOBT appears to be the most suitable CRC index 
screening tool for the average-risk population, with 
FS as an alternative. 
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